TEM · Software & SaaS · Healthcare

Tempus AI, Inc.

$75.89−4.5%Close 11/12

Compare TEM with another stock

What it sells: Diagnostics is 75% of revenue (fiscal year to Dec 2025), up from 68% two years earlier.
Growing?: Yes: revenue up 23% on a year earlier (quarter ended Sep 2026).
Expensive?: Price-to-sales (P/S) 9.2×. Above the peer median of 9.0x. The market pays more per $1 of revenue than for peers.
Analysts?: 50% of 20 say buy; average 12-month target $89.56, 18% above today's price.
Risky?: Much swingier than most large companies: its price swung 76% over the past year (the S&P 500's 14%), and it fell as much as 60% since Jun 2024.

Market cap$13.8B

Revenue (TTM)$1.5B

Net income (TTM)−$189M

P/E (trailing)—

52-week closing range$42 – $85

Dividend yieldNo dividend

Tempus AI, Inc. is a precision medicine company that applies AI to large-scale clinical and molecular datasets and provides diagnostic testing plus software applications (e.g., One, Hub, Next, Lens, Pixel, Link) embedded in provider workflows (including EHR integrations).

More about Tempus AI

It generates revenue primarily from testing/diagnostics services and from subscriptions/fees for data, analytics, and software-enabled services used by healthcare providers and life-science customers.

Market Position

Tempus is positioned as a scaled, data-centric platform in AI-enabled precision medicine, differentiated by its multimodal real-world data (clinical + molecular + imaging) and workflow-level connectivity across a large network of care sites/institutions, enabling use cases like clinical trial matching and clinical decision support.

Key Segments

Key activities include (1) AI-enabled diagnostics / genomics testing and (2) an applications & data/analytics platform used for provider workflow tools and research/biopharma use cases such as the TIME Network.

How has the stock done?

Over the past year TEM rose 6.7%; the health care ETF (XLV) rose 22.9% and the S&P 500 rose 10.8%.

TEM +6.7%Health care ETF (XLV) +22.9%Earnings released

How much it movesRisk

Biggest fall

−60%

From Oct 8, 2025 to Jul 29, 2026, the deepest drop from a high since Jun 2024

Volatility, past year

76%

How much the price swings in a year; the S&P 500's was 14%

Beta, past year

2.42

When the S&P 500 moves 1%, the stock has moved about 2.4% the same way

Show the earnings releases

Released	Quarter	Revenue	EPS vs estimate	Stock, day after	5 days after
Nov 2, 2026	ended Sep 2026	$412M (+23% vs a year earlier)	$0.07 vs −$0.08 (beat)	+7.7%	+16.9%
Jul 30, 2026	ended Jun 2026	$382M (+22% vs a year earlier)	$0.03 vs −$0.52 (beat)	+5.6%	+11.0%
May 5, 2026	ended Mar 2026	$348M (+36% vs a year earlier)	−$0.13 vs −$0.20 (beat)	−4.1%	−15.9%
Feb 24, 2026	ended Dec 2025	$367M (+83% vs a year earlier)	−$0.04 vs −$0.05 (beat)	−6.2%	−10.3%

Change in closing price from the first day shown, or with Price the closing price itself. Prices: Yahoo Finance, to Nov 12, 2026. Dashed lines: the days the company released earnings (its SEC 8-K filings); EPS estimates: Yahoo Finance. The stock's move after a release runs from the last close before its day to the close the day after (or five days after), so a release before the open counts like one after the close.

Is the business growing?

Revenue was $412M in the quarter ended Sep 2026, up 23% from a year earlier.

Revenue by quarter

Change from the same quarter a year earlier

Show the data

Quarter ended	Revenue	vs a year earlier
Mar 2023	$116M	—
Jun 2023	$132M	—
Sep 2023	$136M	—
Dec 2023	$148M	—
Mar 2024	$146M	+26%
Jun 2024	$166M	+25%
Sep 2024	$181M	+33%
Dec 2024	$201M	+36%
Mar 2025	$256M	+75%
Jun 2025	$315M	+90%
Sep 2025	$334M	+85%
Dec 2025	$367M	+83%
Mar 2026	$348M	+36%
Jun 2026	$382M	+22%
Sep 2026	$412M	+23%

Revenue went from $321M in FY22 to $1.3B in FY25; net income from −$290M to −$245M.

RevenueNet income

Show the data

Fiscal year	Revenue	Net income
FY22	$321M	−$290M
FY23	$532M	−$214M
FY24	$693M	−$706M
FY25	$1.3B	−$245M

Revenue by productFiscal years, from Tempus AI's 10-K

In the fiscal year to Dec 2025, Diagnostics was 75% and Insights Product was 20% of revenue; Diagnostics rose from 68% in the fiscal year to Dec 2023.

DiagnosticsInsights ProductTrials ProductAI Applications

Show the data

Fiscal year	Part	Revenue	Share
FY2023	Diagnostics	$363M	68%
FY2023	Insights Product	$118M	22%
FY2023	Trials Product	$46M	9%
FY2023	AI Applications	$5.1M	1%
FY2024	Diagnostics	$452M	65%
FY2024	Insights Product	$187M	27%
FY2024	Trials Product	$42M	6%
FY2024	AI Applications	$12M	2%
FY2025	Diagnostics	$955M	75%
FY2025	Insights Product	$258M	20%
FY2025	Trials Product	$38M	3%
FY2025	AI Applications	$20M	2%

Earnings per shareDiluted, GAAP

EPS, quarter ended Sep 2026

−$0.08

A year earlier −$0.46

EPS, last four quarters

−$1.07

Diluted, from SEC filings

Quarters: Tempus AI, Inc.'s SEC filings, named by the month they end. Fiscal years: Tempus AI, Inc.'s annual reports to the SEC.

How it makes money

The company loses $19.3 for every $100 of revenue. Operating expenses exceed all of gross profit.

Where each $1 of revenue goesFiscal year ended 2025-12-31

Revenue

Total sales

$1.3B100%

Gross profit

Revenue minus direct costs

$798M62.7% of revenue

Cost of revenue

Direct cost of making or buying goods

$474M37.3% of revenue

Operating loss

Expenses above gross profit

−$253M−19.9% of revenue

Net loss

The bottom-line loss

−$245M−19.3% of revenue

Gross margin, fiscal year

62.7%

+22.1 pts over 3 years

Operating margin, fiscal year

−19.9%

+62.9 pts over 3 years

Net margin, fiscal year

−19.3%

+71.1 pts over 3 years

Each margin is that line of the income statement divided by revenue. Fiscal year: Tempus AI, Inc.'s annual reports to the SEC.

How much goes into research?

Tempus AI spent $197M on research and development in the four quarters to Sep 2026, 13.1% of its revenue, against 13.8% a year earlier. Over the year its research spending rose 29.8% and its revenue rose 36.6%.

Research and development, last four quarters

$197M

Up 29.8% on the four quarters before

Share of revenue, last four quarters

13.1%

13.8% a year earlier

Research as a share of revenue over five years

Tempus AI 13.1%

Research and developmentBy quarter

Show the data

Quarter ended	Research and development	Revenue	Share of revenue, four quarters
Dec 2023	$24M	$148M	—
Mar 2024	$24M	$146M	16.7%
Jun 2024	$68M	$166M	23.5%
Sep 2024	$27M	$181M	22.5%
Dec 2024	$30M	$201M	21.5%
Mar 2025	$36M	$256M	20.0%
Jun 2025	$42M	$315M	14.1%
Sep 2025	$45M	$334M	13.8%
Dec 2025	$50M	$367M	13.6%
Mar 2026	$48M	$348M	13.6%
Jun 2026	$53M	$382M	13.7%
Sep 2026	$46M	$412M	13.1%

From Tempus AI, Inc.'s SEC filings: research and development expense by quarter, the fourth being the year minus nine months; its share is the four quarters' expense over their revenue. Some companies count the research they buy, through licences and acquisitions, in this line, so it jumps in the quarter they pay; others report that on a line of its own, not shown here.

Customers and suppliers

In its latest annual report Tempus AI buys from Illumina, Roche, Integrated DNA Technologies and 3 more; sells to Recursion, AstraZeneca, GSK and 1 more.

Along the supply chainTwo steps either way, as each company’s latest annual report names the others

Their suppliers

AppLovin APPto Alphabet

Celestica CLSto Alphabet, Amazon

Marvell Technology MRVLto Alphabet

e.l.f. Beauty ELFto Amazon

United Parcel Service UPSto Amazon

Applied Optoelectronics AAOIto Amazon

Suppliers

Illumina ILMN 33%

Alphabet GOOGL

Amazon AMZN

Integrated DNA Technologies

Roche RO.SW

Tecan US

TEMTempus AI

Customers

AstraZeneca AZN

GSK GSK

Recursion RXRX

SB Tempus

Partners

SoftBank SFTBFCo-owns Japanese precision medicine joint venture50% of SB Tempus; ¥15 billion ($95.2 million) contributed in July 2024

SB TempusJapanese sequencing and patient data joint venture50% equity interest; ¥15 billion ($95.2 million) contributed in July 2024

Personalis PSNLTempus AI invested in it · Equity investment and diagnostic test commercializationLess than 20% of outstanding common stock

Recursion RXRXTempus AI invested in it · Equity investment alongside data licensing relationship

PathosTempus AI invested in it · Warrant investment and drug development commercializationWarrant for 23,456,790 shares, approximately 15% of then-current equity, at $0.0125 per share

Alphabet GOOGLStrategic cloud partnership

AstraZeneca AZNLicenses data and develops oncology foundation model

GSK GSKStrategic collaboration

Changes since the previous annual report (10-K filed Feb 24, 2025)

Tecan USNamed for the first time, as a supplier

PerkinsElmerNo longer named (was a supplier)

ONCare AllianceNo longer named (was a partner)

Illumina ILMNSupplier, share39% → 33%

Show the filing's words

Company	Role	In the filing's words
Illumina	supplier	“We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that we use in our laboratory operations. Purchases from this supplier accounted for approximately 33%, 39% and 33% of total vendor payments for the years ended December 31, 2025, 2024 and 2023, respectively.”
Roche	supplier	“Illumina, Inc., is our primary supplier of sequencers and laboratory reagents; however, we purchase laboratory supplies from other companies as well, such as Roche Holdings, Inc., Integrated DNA Technologies, and Tecan US, Inc.”
Integrated DNA Technologies	supplier	“Illumina, Inc., is our primary supplier of sequencers and laboratory reagents; however, we purchase laboratory supplies from other companies as well, such as Roche Holdings, Inc., Integrated DNA Technologies, and Tecan US, Inc.”
Tecan US	supplier	“Illumina, Inc., is our primary supplier of sequencers and laboratory reagents; however, we purchase laboratory supplies from other companies as well, such as Roche Holdings, Inc., Integrated DNA Technologies, and Tecan US, Inc.”
Amazon	supplier	“In addition to suppliers who provide products supporting our provision of laboratory tests, we have cloud agreements with both AWS and Google.”
Alphabet	supplier	“In June 2020, we signed a multi-year strategic partnership with Google that included an agreement through which Tempus procures extensive cloud services from Google.”
Alphabet	partner	“In June 2020, we signed a multi-year strategic partnership with Google that included an agreement through which Tempus procures extensive cloud services from Google. The cloud agreement includes a convertible note that is reduced as we procure services from Google and also contemplates co-innovation projects that we may work on with Google from time to time.”
Personalis	partner · Tempus AI invested in it	“The Company owns less than 20% of Personalis' outstanding common stock and has no significant influence or control over Personalis.”
Recursion	customer	“In exchange for these rights, Recursion will pay an initial license fee of $22 million and an annual license fee throughout the term of the agreement, which, together with the initial license fee, totals up to $160 million. The term of the Recursion Agreement will continue through November 3, 2028, unless terminated sooner.”
Recursion	partner · Tempus AI invested in it	“We hold shares of common stock of Recursion and Personalis, Inc., or Personalis, which are recorded within marketable equity securities.”
AstraZeneca	customer	“Remaining TCV includes the total potential value of the company’s strategic collaborations with AstraZeneca AB, or AstraZeneca, and GlaxoSmithKline, or GSK, which, although listed under the Data and applications product line, could be satisfied by the purchase of any of the company’s products and services.”
AstraZeneca	partner · licensing deal with it	“In April 2025, we entered into a series of agreements with AstraZeneca AB, or AstraZeneca, and Pathos regarding both the development of a foundation large multimodal model in the field of oncology, or the Foundation Model, and the licensing of certain de-identified multi-modal data to assist in the development of the Foundation Model.”
GSK	customer	“Remaining TCV includes the total potential value of the company’s strategic collaborations with AstraZeneca AB, or AstraZeneca, and GlaxoSmithKline, or GSK, which, although listed under the Data and applications product line, could be satisfied by the purchase of any of the company’s products and services.”
GSK	partner	“Remaining TCV includes the total potential value of the company’s strategic collaborations with AstraZeneca AB, or AstraZeneca, and GlaxoSmithKline, or GSK, which, although listed under the Data and applications product line, could be satisfied by the purchase of any of the company’s products and services.”
Pathos	partner · Tempus AI invested in it	“On August 19, 2021, the Company entered into a Master Agreement with Pathos, which was subsequently amended on February 12, 2024 (as amended, the "Amended and Restated Master Agreement"), for the purpose of furthering the commercialization efforts of drug development. In connection therewith, the Company received a warrant to purchase 23,456,790 shares, or approximately 15% of the then current outstanding equity in Pathos, for $0.0125 per share.”
SoftBank	partner · joint venture with it	“The Joint Venture closed on July 18, 2024, at which time the Company and SoftBank each contributed ¥15 billion ($95.2 million). Each party received 50% of SB Tempus's outstanding capital stock and board seats.”
SB Tempus	partner · joint venture with it	“The Joint Venture closed on July 18, 2024, at which time the Company and SoftBank each contributed ¥15 billion ($95.2 million). Each party received 50% of SB Tempus's outstanding capital stock and board seats.”
SB Tempus	customer	“Under the Data License Agreement, SB Tempus paid the Company ¥7.5 billion ($47.9 million) in exchange for the license to an initial records batch, which is recorded in deferred revenue and will be recognized into Data and applications revenue over the term of the license subscription which ends on March 31, 2026. For the years ended December 31, 2025, 2024 and 2023, the Company recognized $25.0 million, $16.6 million and $0, respectively, in Data and applications revenue related to the Data License Agreement.”

Only the companies Tempus AI names in its 10-K filed Feb 24, 2026 (SEC). The supply chain joins the latest annual reports of the companies on it and the 8-Ks they filed since: a link shows when either side's report names the other, so it grows as more reports are read. Hover a name for the filing's own words.

Is it expensive?

Currently unprofitable, so P/E does not apply, so we look at price-to-sales instead: 9.2x, above the peer median of 9.0x. Revenue is up 23% from a year ago.

9.2×Price-to-sales (P/S)

Above the peer median of 9.0x. The market pays more per $1 of revenue than for peers.

Vs. peersPrice-to-sales (x)

TEMPeersPeer median 9.0x

Show the data

Company	Price-to-sales (P/S)
VEEV · Veeva Systems Inc.	14.2×
HNGE · Hinge Health, Inc.	12.3×
TEM · Tempus AI, Inc.	9.2×
DOCS · Doximity, Inc.	9.0×
HQY · HealthEquity, Inc.	6.3×
BTSG · BrightSpring Health Services, Inc.	0.9×

Tempus AI, Inc. is currently unprofitable, so P/E does not apply. We use price-to-sales instead: market cap as a multiple of revenue.

What analysts expect

The average analyst price target is $89.56, 18% above the current price; 50% of 20 analysts rate it a buy; earnings beat estimates in all of the last 4 quarters.

12-month price targetsCurrent price $75.89

12 mo agoTodayIn 12 mo

High target

$120+58%

Average target

$89.56+18%

Low target

$70.00−8%

Ratings20 analysts

Strong Buy 2Buy 8Hold 10Sell 0Strong Sell 0

Buy or Strong Buy: 10 analysts (50%). Sell or Strong Sell: 0.

Targets and ratings over the past year49 changes by 19 firms

Over the past year the average of the analysts' latest price targets went from $88.12 to $79.94 (−9%), while TEM went from $67.94 to $75.89 (+12%). In the past three months targets were raised 15 times and never cut. 2 upgrades and no downgrades over the year; the latest: Jefferies moved it to Hold from Underperform on Nov 3, 2026.

Average target $79.94TEMMiddle half of targetsUpgrade

Targets raised, by monthTargets cut

Show every change

Date	Firm	Change	Rating	Target
Nov 3, 2026	Freedom Capital Markets	Target raised	Hold	$89.00, was $73.00
Nov 3, 2026	HC Wainwright & Co.	Target raised	Buy	$85.00, was $68.00
Nov 3, 2026	Baird	Target raised	Outperform	$92.00, was $85.00
Nov 3, 2026	Cantor Fitzgerald	Target raised	Overweight	$92.00, was $80.00
Nov 3, 2026	Jefferies	Upgrade	Hold, was Underperform	$70.00, was $35.00
Nov 3, 2026	BTIG	Target raised	Buy	$100.00, was $80.00
Nov 2, 2026	Needham	Target raised	Buy	$89.00, was $75.00
Oct 26, 2026	HC Wainwright & Co.	Target raised	Buy	$68.00, was $66.00
Oct 26, 2026	BTIG	Target kept	Buy	$80.00
Oct 23, 2026	Needham	Target kept	Buy	$75.00
Oct 14, 2026	JP Morgan	Target raised	Neutral	$70.00, was $45.00
Oct 12, 2026	Canaccord Genuity	Target raised	Buy	$95.00, was $80.00
Oct 1, 2026	Guggenheim	Target raised	Buy	$92.00, was $65.00
Sep 21, 2026	Goldman Sachs	Began coverage	Neutral	$75.00
Sep 11, 2026	HC Wainwright & Co.	Target raised	Buy	$66.00, was $56.00
Sep 9, 2026	UBS	Began coverage	Neutral	$70.00
Sep 8, 2026	Rothschild & Co	Began coverage	Neutral	$67.00
Sep 8, 2026	Roth Capital	Began coverage	Neutral	$67.00
Sep 2, 2026	Cantor Fitzgerald	Began coverage	Overweight	$80.00
Sep 1, 2026	Piper Sandler	Upgrade	Overweight, was Neutral	$76.00, was $56.00
Aug 31, 2026	Freedom Capital Markets	Target raised	Hold	$73.00, was $51.00
Aug 20, 2026	BTIG	Target raised	Buy	$80.00, was $70.00
Aug 4, 2026	Piper Sandler	Target cut	Neutral	$56.00, was $58.00
Aug 3, 2026	BTIG	Target cut	Buy	$70.00, was $80.00
Aug 3, 2026	HC Wainwright & Co.	Target cut	Buy	$56.00, was $64.00
Aug 3, 2026	Stifel	Target cut	Hold	$50.00, was $60.00
Jul 31, 2026	Needham	Target kept	Buy	$75.00
Jul 20, 2026	Needham	Target kept	Buy	$75.00
Jul 16, 2026	Guggenheim	Target raised	Buy	$65.00, was $60.00
Jul 1, 2026	Freedom Capital Markets	Began coverage	Hold	$59.00
Jun 1, 2026	Needham	Target kept	Buy	$75.00
Jun 1, 2026	BTIG	Target kept	Buy	$80.00
May 11, 2026	HC Wainwright & Co.	Target cut	Buy	$64.00, was $95.00
May 8, 2026	BTIG	Target cut	Buy	$80.00, was $90.00
May 6, 2026	TD Cowen	Target raised	Buy	$68.00, was $65.00
Apr 13, 2026	Jefferies	Began coverage	Underperform	$35.00
Mar 30, 2026	Guggenheim	Target cut	Buy	$60.00, was $95.00
Mar 11, 2026	Needham	Target kept	Buy	$75.00
Mar 9, 2026	HC Wainwright & Co.	Target raised	Buy	$95.00, was $89.00
Mar 3, 2026	Morgan Stanley	Target cut	Overweight	$70.00, was $85.00
Feb 25, 2026	JP Morgan	Target cut	Neutral	$60.00, was $80.00
Feb 25, 2026	Needham	Target cut	Buy	$75.00, was $100.00
Feb 25, 2026	BTIG	Target cut	Buy	$90.00, was $105.00
Feb 19, 2026	Mizuho	Began coverage	Outperform	$100.00
Feb 17, 2026	Baird	Began coverage	Outperform	$59.00
Dec 22, 2025	Canaccord Genuity	Target cut	Buy	$80.00, was $95.00
Dec 15, 2025	JP Morgan	Target cut	Neutral	$80.00, was $85.00
Dec 2, 2025	Morgan Stanley	Target raised	Overweight	$85.00, was $80.00
Nov 25, 2025	BTIG	Target raised	Buy	$105.00, was $96.00

Earnings against estimatesLast 4 quarters, per share

Average estimateReported, beat

Show the data

Quarter	Estimate	Reported	Surprise
Dec ’25	−$0.05	−$0.04	+20.0%
Mar ’26	−$0.20	−$0.13	+35.0%
Jun ’26	−$0.52	$0.03	+105.8%
Sep ’26	−$0.08	$0.07	+187.5%

The day after each of these reports the stock moved −6.2% (Dec 2025, beat); −4.1% (Mar 2026, beat); +5.6% (Jun 2026, beat); +7.7% (Sep 2026, beat).

Expected nextConsensus of Nov 10, 2026

For the quarter ending Dec 2026, analysts expect adjusted earnings of $0.03 a share, against a loss of $0.04 a year earlier. For the fiscal year ending Dec 2027, they expect revenue of $2.0B, up 24% on the year before's estimate.

EPS, quarter ending Dec 2026

$0.03

Adjusted. Dec 2025: a loss of $0.04; range −$0.05 to $0.10; 13 analysts

Revenue, year ending Dec 2027

$2.0B+24% on the year before's estimate

The year to Dec 2026: $1.6B expected; range $1.9B to $2.1B; 19 analysts

Show the data

Period	Figure	Expected	Low to high	Analysts	A year earlier	Change
Quarter ending Dec 2026	EPS (adjusted)	$0.03	−$0.05 to $0.10	13	−$0.04 (Dec 2025)	—
Year ending Dec 2026	Revenue	$1.6B	$1.6B to $1.6B	20	$1.3B (year to Dec 2025)	+26%
Year ending Dec 2027	Revenue	$2.0B	$1.9B to $2.1B	19	$1.6B (expected, year to Dec 2026)	+24%

Targets, ratings and earnings estimates: Yahoo Finance. Rating and target changes: Yahoo Finance's list of upgrades and downgrades. The average target on each day is the average of every listed firm's latest target set in the 180 days before it, so it counts fewer analysts than the average target above, and the band is the middle half of those targets (a quarter of the firms are above it, a quarter below); a target set before a stock split is divided by the split. Expected figures: the average of the analysts' estimates (Yahoo Finance). Their EPS is adjusted, as analysts estimate it, so it is set against the adjusted EPS Yahoo reports for the same quarters, not the GAAP EPS of the growth and valuation sections; revenue against the SEC filings. No change is given against a quarter whose reported EPS was more than 50% off its own estimate (often a one-off gain or charge), nor against a year that counts one. Each estimate is pinned to its fiscal period by the report date or the period's end, and one that cannot be is left out.

Where the cash goes

Capex of $29M exceeds operating cash flow of −$108M, leaving free cash flow of −$137M. The gap has to be covered with cash on hand or borrowing.

Where a year of cash went4 quarters to Sep 2026

Show the data

Line	Amount
Op. cash flow	−$108M
Capex	−$29M
Free cash flow	−$137M
Dividends	—
Buybacks	—
Cash retained	−$137M

Free cash flow yield

−1.0%

Free cash flow is negative, so the company is burning cash.

Dividend yield

No dividend

No dividend today; cash goes to growth and share buybacks.

By quarter: free cash flow and what went back to shareholdersLast 12 quarters

Free cash flowDividendsBuybacks

Show the data

Quarter ended	Free cash flow	Dividends	Buybacks
Dec 2023	−$43M	$0	$0
Mar 2024	−$107M	—	—
Jun 2024	−$105M	—	—
Sep 2024	$49M	$0	$0
Dec 2024	−$47M	$0	$0
Mar 2025	−$108M	—	—
Jun 2025	$37M	—	—
Sep 2025	−$127M	$0	—
Dec 2025	−$42M	$0	—
Mar 2026	−$81M	—	—
Jun 2026	−$14M	—	—
Sep 2026	−$122K	—	—

Free cash flow: operating cash flow minus capital spending on property, plant and equipment, from SEC filings, for the last 4 quarters and by quarter.

Financial health

Current ratio 3.1, no pressure to repay short-term debt; debt-to-equity 2.5, debt is high, which adds pressure if the economy weakens.

Current ratio

3.1Strong liquidity

Assets that can be turned into cash soon are 3.1x what is owed within a year. 1.5 or higher is comfortable; below 1 needs watching.

Debt-to-equity

2.5High debt

For every $1 of shareholder funds, there is $2.5 of debt (leases not counted). The higher the number, the more pressure when the economy weakens.

Net debt

$485MMore debt than cash

Cash and short-term investments of $755M against debt of $1.2B. Lease obligations of $88M are not counted: they are rent owed, not money borrowed. It also holds $87M of long-term investments, which can be stakes in other companies rather than cash.

AssetsTotal ~$2.3B

Cash

$600M26.6%

Investments

$240M10.4%

Receivables

$310M13.7%

Inventory

$50M2.3%

Property & equipment

$150M6.8%

Goodwill

$470M20.7%

Intangibles

$360M15.6%

Other

$90M3.9%

Liabilities & equityTotal ~$2.3B

Current

$370M16.4%

Long-term

$1.4B62.0%

Equity

$490M21.6%

Latest fiscal year balance sheet. Source: Yahoo Finance.

Who holds it

In the filings of 2 members of Congress and 7 funds whose copy leaves TEM out (on the exchange, not in the app yet): Patient Capital Management, Baillie Gifford &, Nancy Pelosi, Temasek Holdings (Private), Canada Pension Plan Investment Board, Rob Bresnahan and 3 more.

What did the funds Hunch tracks do?

Of the 83 funds whose 13F filings Hunch reads, 10 held TEM at the end of their latest quarter (for most, Q2 2026). Over that quarter 4 added shares, 4 cut, 2 sold all and 2 held the same. The largest of them is ARK Investment Management, 10.02M shares worth $581M at Jun 30, 2026, 4.3% more than a quarter earlier.

Funds that added shares

Over their latest quarter

Funds that cut

2 of them sold all

Each fund's change in sharesChange in shares over the latest quarter

Added or newCut or sold all

Show every fund

Fund	Quarter	Shares	Value	Change in shares	Change	Filed
ARK Investment Management	Q2 2026	10.02M	$581M	+414,889	+4.3%	Aug 14, 2026
Baillie Gifford &	Q3 2026	6.91M	$566M	−1.28M	−16%	Nov 9, 2026
Softbank Group	Q2 2026	5.41M	$313M	0	0.0%	Aug 14, 2026
Norges Bank	Q2 2026 vs Q4 2025	975,302	$56.5M	+158,462	+19%	Aug 12, 2026
Canada Pension Plan Investment Board	Q2 2026	723,100	$41.9M	−2,000	−0.3%	Aug 14, 2026
Patient Capital Management	Q3 2026	254,004	$20.8M	−146,694	−37%	Nov 12, 2026
Swiss National Bank	Q3 2026	211,700	$17.3M	+1,700	+0.8%	Nov 12, 2026
Temasek Holdings (Private)	Q3 2026	133,046	$10.9M	+33,730	+34%	Oct 28, 2026
Mirae Asset Global Investments	Q3 2026	65,114	$5.3M	−13,683	−17%	Nov 3, 2026
Tudor Investment Corp Et Al	Q2 2026	0	—	−26,935	Sold all	Aug 14, 2026
H&H International Investment	Q2 2026	20,000	$1.2M	0	0.0%	Aug 14, 2026
Nomura Holdings	Q2 2026	0	—	−17,041	Sold all	Aug 14, 2026

From the 13F filings of the 83 funds Hunch tracks, not of every institution: each fund's shares of TEM at its latest quarter end against the quarter before, as filed (long positions only, options left out), the quarter before put on the latest quarter's share count across a split. A fund files 45 days after its quarter ends, so some have a newer quarter than others. Value is at the quarter end. Norges Bank filed its 13F for Q1 2026 confidentially, with no holdings made public, so its row compares Q2 2026 with Q4 2025.

Are insiders buying or selling?

Officers and directors sold $188M of TEM on the open market in the 12 months to Nov 12, 2026; none bought. 100% of the sales were made under 10b5-1 plans, set up in advance. The largest was Eric P Lefkofsky (CEO and Chairman; director), who sold $169M in 152 sales.

Sold

$188M

214 sales

Bought

None

0 purchases

Under 10b5-1 plans

100%

Share of the sales' value

Trades on the priceA dot a day, sized by value

TEMSaleSale under a 10b5-1 plan

Who tradedOpen-market trades, last 12 months

Eric P Lefkofsky

CEO and Chairman; director · 100% under a 10b5-1 plan

−$169M152 trades

Ryan Fukushima

CEO, Data · 100% under a 10b5-1 plan

−$8.3M22 trades

James William Rogers

Chief Financial Officer · 100% under a 10b5-1 plan

−$4.3M6 trades

Andrew Polovin

EVP, Chief Legal Officer · 100% under a 10b5-1 plan

−$2.7M9 trades

Thomas Edward Schoenherr

CEO, Diagnostics · 100% under a 10b5-1 plan

−$1.5M8 trades

Show every trade

Date	Insider	Role	Trade	Shares	Price	Value	Filed
Nov 2, 2026	David R Epstein	Director	Sale (10b5-1 plan)	370	$74.29	$27K	Nov 4, 2026
Nov 2, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	80	$74.29	$5,943	Nov 4, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	10,428	$67.36	$702K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	7,592	$68.00	$516K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,495	$69.28	$104K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,312	$70.58	$446K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	16,414	$71.56	$1.2M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	15,259	$72.31	$1.1M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	24,597	$67.36	$1.7M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	17,825	$68.00	$1.2M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,510	$69.28	$243K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,820	$70.58	$1.0M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	38,489	$71.56	$2.8M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	35,759	$72.31	$2.6M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,282	$67.36	$86K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	961	$68.00	$65K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	195	$69.28	$14K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	824	$70.58	$58K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,167	$71.56	$155K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,071	$72.31	$150K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,132	$67.36	$615K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,636	$68.00	$451K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,300	$69.28	$90K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	5,486	$70.58	$387K	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,237	$71.56	$1.0M	Oct 29, 2026
Oct 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	13,209	$72.31	$955K	Oct 29, 2026
Sep 25, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	10,281	$85.00	$874K	Sep 29, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	7,394	$76.57	$566K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	33,770	$77.29	$2.6M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	16,152	$78.23	$1.3M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	184	$78.86	$15K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	17,359	$76.57	$1.3M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	79,259	$77.29	$6.1M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	37,950	$78.23	$3.0M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	432	$78.86	$34K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	965	$76.57	$74K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	4,420	$77.29	$342K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,091	$78.23	$164K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	24	$78.86	$1,893	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,431	$76.57	$492K	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	29,367	$77.29	$2.3M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,042	$78.23	$1.1M	Sep 24, 2026
Sep 22, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	160	$78.86	$13K	Sep 24, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	52,558	$80.52	$4.2M	Sep 18, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	4,942	$81.09	$401K	Sep 18, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	123,391	$80.52	$9.9M	Sep 18, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	11,609	$81.09	$941K	Sep 18, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,855	$80.52	$552K	Sep 18, 2026
Sep 17, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	645	$81.09	$52K	Sep 18, 2026
Sep 17, 2026	Ryan M Bartolucci	Chief Accounting Officer	Sale (10b5-1 plan)	7,062	$75.00	$530K	Sep 18, 2026
Sep 17, 2026	Andrew Polovin	EVP, Chief Legal Officer	Sale (10b5-1 plan)	2,951	$75.00	$221K	Sep 18, 2026
Sep 16, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	700	$70.00	$49K	Sep 18, 2026
Sep 1, 2026	David R Epstein	Director	Sale (10b5-1 plan)	250	$65.55	$16K	Sep 3, 2026
Sep 1, 2026	Jennifer A Doudna	Director	Sale (10b5-1 plan)	676	$65.55	$44K	Sep 3, 2026
Sep 1, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	13,046	$62.12	$810K	Sep 3, 2026
Sep 1, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	10,900	$62.64	$683K	Sep 3, 2026
Sep 1, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	5,900	$63.80	$376K	Sep 3, 2026
Sep 1, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	1,000	$64.63	$65K	Sep 3, 2026
Aug 28, 2026	Nadja West	Director	Sale (10b5-1 plan)	3,000	$69.00	$207K	Sep 1, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	760	$64.03	$49K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,168	$64.70	$140K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,944	$65.98	$260K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	4,218	$67.01	$283K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	10,282	$68.13	$701K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	22,495	$68.97	$1.6M	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	12,851	$69.83	$897K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	782	$70.58	$55K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,789	$64.03	$115K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	5,093	$64.70	$330K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,262	$65.98	$611K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,935	$67.01	$666K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	24,161	$68.13	$1.6M	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	52,784	$68.97	$3.6M	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	30,139	$69.83	$2.1M	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,837	$70.58	$130K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	101	$64.03	$6,467	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	284	$64.70	$18K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	515	$65.98	$34K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	578	$67.01	$39K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,365	$68.13	$93K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,887	$68.96	$199K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,668	$69.83	$116K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	102	$70.58	$7,199	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	660	$64.03	$42K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,883	$64.70	$122K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,429	$65.98	$226K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,649	$67.01	$245K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,926	$68.13	$608K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	19,605	$68.97	$1.4M	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	11,167	$69.83	$780K	Aug 27, 2026
Aug 25, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	681	$70.58	$48K	Aug 27, 2026
Aug 21, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	14,286	$70.00	$1.0M	Aug 25, 2026
Aug 21, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	2,694	$70.00	$189K	Aug 25, 2026
Aug 19, 2026	Andrew Polovin	EVP, Chief Legal Officer	Sale (10b5-1 plan)	7,927	$56.00	$444K	Aug 20, 2026
Aug 19, 2026	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	26,313	$60.00	$1.6M	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	3,094	$55.97	$173K	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	100	$56.47	$5,647	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	500	$57.94	$29K	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	2,994	$59.97	$180K	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	900	$60.45	$54K	Aug 20, 2026
Aug 19, 2026	Thomas Edward Schoenherr	CEO, Diagnostics	Sale (10b5-1 plan)	494	$61.23	$30K	Aug 20, 2026
Aug 14, 2026	Nadja West	Director	Sale (10b5-1 plan)	3,000	$53.90	$162K	Aug 18, 2026
Aug 7, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	20,000	$50.04	$1.0M	Aug 11, 2026
Aug 3, 2026	David R Epstein	Director	Sale (10b5-1 plan)	370	$43.40	$16K	Aug 5, 2026
Aug 3, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	1,000	$43.25	$43K	Aug 5, 2026
Aug 3, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	1,300	$44.33	$58K	Aug 5, 2026
Aug 3, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	3,100	$45.33	$141K	Aug 5, 2026
Aug 3, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	15,856	$46.57	$738K	Aug 5, 2026
Aug 3, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	2,562	$46.94	$120K	Aug 5, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	20,472	$41.34	$846K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	30,906	$42.36	$1.3M	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,122	$42.95	$263K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	48,066	$41.34	$2.0M	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	72,560	$42.36	$3.1M	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,374	$42.95	$617K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,671	$41.34	$110K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	4,031	$42.36	$171K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	798	$42.95	$34K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	17,801	$41.34	$736K	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	26,875	$42.36	$1.1M	Jul 30, 2026
Jul 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	5,324	$42.95	$229K	Jul 30, 2026
Jul 8, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	13,984	$56.80	$794K	Jul 10, 2026
Jul 8, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	13,686	$57.37	$785K	Jul 10, 2026
Jul 8, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	3,477	$58.55	$204K	Jul 10, 2026
Jul 8, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	2,137	$59.47	$127K	Jul 10, 2026
Jul 6, 2026	Ryan Fukushima	CEO, Data	Sale (10b5-1 plan)	10,000	$60.00	$600K	Jul 8, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,317	$55.38	$128K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,430	$56.51	$533K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	10,293	$57.13	$588K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,080	$58.30	$121K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,130	$59.23	$541K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	9,271	$55.38	$513K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	37,711	$56.51	$2.1M	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	41,178	$57.13	$2.4M	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,320	$58.30	$485K	Jul 1, 2026
Jun 29, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	36,520	$59.23	$2.2M	Jul 1, 2026
Jun 25, 2026	Jennifer A Doudna	Director	Sale (10b5-1 plan)	2,673	$55.00	$147K	Jun 29, 2026
Jun 25, 2026	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	11,529	$55.00	$634K	Jun 29, 2026
Jun 1, 2026	David R Epstein	Director	Sale (10b5-1 plan)	250	$49.40	$12K	Jun 3, 2026
May 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,932	$46.17	$412K	May 29, 2026
May 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	24,318	$46.89	$1.1M	May 29, 2026
May 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	35,721	$46.17	$1.6M	May 29, 2026
May 27, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	97,279	$46.89	$4.6M	May 29, 2026
Apr 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	26,360	$51.03	$1.3M	Apr 30, 2026
Apr 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,890	$51.52	$355K	Apr 30, 2026
Apr 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	105,430	$51.03	$5.4M	Apr 30, 2026
Apr 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	27,570	$51.52	$1.4M	Apr 30, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	16,388	$45.78	$750K	Mar 27, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,915	$46.91	$700K	Mar 27, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,947	$47.42	$92K	Mar 27, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	65,559	$45.78	$3.0M	Mar 27, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	59,657	$46.91	$2.8M	Mar 27, 2026
Mar 26, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	7,784	$47.42	$369K	Mar 27, 2026
Mar 2, 2026	David R Epstein	Director	Sale (10b5-1 plan)	250	$50.69	$13K	Mar 4, 2026
Mar 2, 2026	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	11,414	$50.69	$579K	Mar 4, 2026
Feb 20, 2026	Andrew Polovin	EVP, Chief Legal Officer	Sale (10b5-1 plan)	10,849	$60.30	$654K	Feb 20, 2026
Feb 20, 2026	Andrew Polovin	EVP, Chief Legal Officer	Sale (10b5-1 plan)	100	$60.97	$6,097	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,552	$58.31	$499K	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	23,775	$59.04	$1.4M	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	923	$59.70	$55K	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	33,717	$58.31	$2.0M	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	95,567	$59.04	$5.6M	Feb 20, 2026
Feb 19, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,716	$59.70	$222K	Feb 20, 2026
Feb 19, 2026	Erik Phelps	EVP, Chief Admin. Officer	Sale (10b5-1 plan)	3,814	$60.00	$229K	Feb 20, 2026
Feb 2, 2026	David R Epstein	Director	Sale (10b5-1 plan)	370	$59.41	$22K	Feb 4, 2026
Jan 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	25,631	$65.41	$1.7M	Jan 30, 2026
Jan 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	7,619	$66.06	$503K	Jan 30, 2026
Jan 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	102,474	$65.41	$6.7M	Jan 30, 2026
Jan 28, 2026	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	30,526	$66.06	$2.0M	Jan 30, 2026
Jan 5, 2026	Ryan Fukushima	Chief Operating Officer	Sale (10b5-1 plan)	5,000	$64.26	$321K	Jan 7, 2026
Jan 2, 2026	Jennifer A Doudna	Director	Sale (10b5-1 plan)	1,250	$60.17	$75K	Jan 6, 2026
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,571	$62.26	$222K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	5,118	$63.08	$323K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	18,960	$64.12	$1.2M	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,800	$64.92	$182K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,801	$66.04	$185K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	14,153	$62.26	$881K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	20,489	$63.08	$1.3M	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	75,913	$64.12	$4.9M	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	11,238	$64.92	$730K	Dec 22, 2025
Dec 18, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	11,207	$66.04	$740K	Dec 22, 2025
Dec 16, 2025	Erik Phelps	EVP & Chief Admin & Legal Off	Sale (10b5-1 plan)	1,302	$67.42	$88K	Dec 18, 2025
Dec 11, 2025	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	4,209	$72.09	$303K	Dec 12, 2025
Dec 11, 2025	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	11,982	$73.31	$878K	Dec 12, 2025
Dec 11, 2025	James William Rogers	Chief Financial Officer	Sale (10b5-1 plan)	3,775	$74.08	$280K	Dec 12, 2025
Dec 5, 2025	Wayne A.I. Frederick	Director	Sale	3,675	$77.23	$284K	Dec 9, 2025
Dec 1, 2025	David R Epstein	Director	Sale (10b5-1 plan)	250	$75.55	$19K	Dec 3, 2025
Dec 1, 2025	Jennifer A Doudna	Director	Sale (10b5-1 plan)	676	$75.55	$51K	Dec 3, 2025
Dec 1, 2025	Ryan Fukushima	Chief Operating Officer	Sale (10b5-1 plan)	904	$74.59	$67K	Dec 3, 2025
Dec 1, 2025	Ryan Fukushima	Chief Operating Officer	Sale (10b5-1 plan)	2,128	$75.59	$161K	Dec 3, 2025
Dec 1, 2025	Ryan Fukushima	Chief Operating Officer	Sale (10b5-1 plan)	1,968	$76.39	$150K	Dec 3, 2025
Nov 24, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	33,250	$74.10	$2.5M	Nov 25, 2025
Nov 24, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	133,000	$74.10	$9.9M	Nov 25, 2025
Nov 24, 2025	Andrew Polovin	EVP and General Counsel	Sale (10b5-1 plan)	12,874	$75.00	$966K	Nov 25, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,221	$65.59	$408K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	6,467	$66.33	$429K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	1,913	$67.39	$129K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	910	$68.38	$62K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	2,041	$69.43	$142K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,074	$70.58	$217K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,841	$71.63	$633K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,783	$72.20	$273K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	24,881	$65.59	$1.6M	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	25,866	$66.33	$1.7M	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	7,660	$67.39	$516K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	3,640	$68.38	$249K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	8,158	$69.43	$566K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	12,295	$70.58	$868K	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	35,362	$71.63	$2.5M	Nov 20, 2025
Nov 20, 2025	Eric P Lefkofsky	CEO and Chairman; director	Sale (10b5-1 plan)	15,138	$72.20	$1.1M	Nov 20, 2025
Nov 19, 2025	Andrew Polovin	EVP and General Counsel	Sale (10b5-1 plan)	828	$66.40	$55K	Nov 20, 2025
Nov 19, 2025	Andrew Polovin	EVP and General Counsel	Sale (10b5-1 plan)	3,307	$67.90	$225K	Nov 20, 2025
Nov 19, 2025	Andrew Polovin	EVP and General Counsel	Sale (10b5-1 plan)	2,052	$68.86	$141K	Nov 20, 2025
Nov 19, 2025	Andrew Polovin	EVP and General Counsel	Sale (10b5-1 plan)	200	$69.41	$14K	Nov 20, 2025

From the Form 4s filed with the SEC about Tempus AI, Inc. (89 in the 12 months): purchases (code P) and sales (code S) on the open market by its officers and directors, at the price each filing gives (often an average of the day's trades). A sale is a 10b5-1 sale when its filing says it was made under such a plan, set up in advance. Not counted: 56 other transactions (grants, shares sold to pay tax and gifts).